Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Net Cash Flow of $106.4 million for Q1 2026, up 366.19% year-over-year from $22.8 million in Q1 2025, and up 189.32% quarter-over-quarter from $36.8 million in Q4 2025.
Scholar Rock Holding (SRRK) Net Cash Flow (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Net Cash Flow history runs 10 years deep, the most recent figure standing at $106.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 366.19% year-over-year to $106.4 million; the TTM figure through Mar 2026 stood at $293.4 million (up 538.46% YoY), while the FY2025 annual figure was $147.1 million, up 93.43% from the prior year.
- Net Cash Flow for Q1 2026 stood at $106.4 million, up from $36.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $205.6 million in Q2 2022, with the low at -$172.7 million in Q3 2022.
- The 5-year median for Net Cash Flow is $1.4 million (2024), against an average of $12.8 million.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 8912.8% in 2022, then soared 976.74% in 2025.
- Scholar Rock Holding's Net Cash Flow stood at -$29.8 million in 2022, then soared by 214.27% to $34.1 million in 2023, then jumped by 198.04% to $101.5 million in 2024, then sank by 63.78% to $36.8 million in 2025, then soared by 189.32% to $106.4 million in 2026.
- Business Quant data shows SRRK's Net Cash Flow at $106.4 million in Q1 2026, $36.8 million in Q4 2025, and $135.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 7.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.31 Mn |
| Jun 30, 2026 | 7.31 Mn |
| Mar 31, 2026 | 106.35 Mn |
| Mar 31, 2026 | 106.35 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Dec 31, 2025 | 36.76 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Sep 30, 2025 | 135.25 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 15.00 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Dec 31, 2024 | 101.49 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Sep 30, 2024 | -16.98 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | -9.88 Mn |
| Mar 31, 2024 | -9.88 Mn |